Mehran Massumi, MD
Interventional Cardiology · Houston, TXNPI 1942521711
Payments from drug & device makers
Across 792 payments — averaging $144.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$59K
- Boston Scientific$16K
- Bard Peripheral Vascular, Inc.$11K
- Cagent Vascular Inc$7K
- Medtronic$5K
- Edwards Lifesciences$3K
- plus $13K from 32 others
Across 1 payment — averaging $165.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$166
What the payments were for
- Consulting fees$44,83139%
- Speaking & faculty fees$22,45020%
- Travel & lodging$18,33116%
- Food & beverage$28,53425%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 208 | $58,677 |
| Boston Scientific | 93 | $16,034 |
| Bard Peripheral Vascular, Inc. | 13 | $10,992 |
| Cagent Vascular Inc | 8 | $7,092 |
| Medtronic(2 entities) | 61 | $4,982 |
| Edwards Lifesciences | 193 | $2,911 |
| Inari Medical, Inc. | 22 | $2,821 |
| Abiomed | 31 | $2,396 |
| Penumbra, Inc. | 7 | $1,942 |
| Cardiovascular Systems Inc. | 53 | $1,536 |
| W. L. Gore & Associates, Inc. | 12 | $823 |
| Endologix LLC | 5 | $474 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $435 |
| Teleflex LLC | 4 | $412 |
| Endotronix, Inc. | 1 | $337 |
| Angiodynamics, Inc. | 2 | $261 |
| Surmodics, Inc. | 2 | $230 |
| Actelion Pharmaceuticals US, Inc. | 8 | $228 |
| Amgen | 12 | $201 |
| Astellas Pharma US Inc | 9 | $195 |
| Pfizer | 9 | $185 |
| Cook Medical LLC | 3 | $154 |
| Johnson & Johnson | 2 | $143 |
| Avinger Inc. | 2 | $126 |
| Shockwave Medical, Inc | 5 | $100 |
| Saranas, Inc. | 1 | $88 |
| AstraZeneca | 5 | $74 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Bridgebio Pharma, Inc. | 1 | $35 |
| Cardiva Medical, Inc. | 1 | $29 |
| Cvrx, Inc. | 1 | $28 |
| Cardinal Health 200 LLC | 1 | $28 |
| Terumo Medical Corporation | 1 | $27 |
| Bayer | 1 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Portola Pharmaceuticals, LLC | 1 | $20 |
| Contego Medical, Inc | 1 | $19 |
| Chiesi USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PERCLOSE PROGLIDE$19,072
- ABSOLUTE PRO$15,021
- LUTONIX$10,512
- SUPERA$10,123
- Serrantor$7,059
- FLOWTRIEVER CATHETER, S$3,211
- Diamondback Peripheral$3,000
- FEMOSTOP$2,500
- Perclose ProStyle$2,400
- Impella$1,875
- Indigo System$1,678
- CT THROMBECTOMY SYSTEM KIT$1,368
- VenaSeal$1,199
- ClosureFast$1,078
- EKOSONIC$1,004
- AngioJet Ultra 5000A$924
- SAPIEN 3 Ultra RESILIA$753
- LOTUS EDGE$692
- JETi Peripheral Catheter$636
- GENERAL VASCULAR ACCESS$602
How this compares
$114,146 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 333 | $353,674 |
| EntrestoSacubitril/Valsartan | 44 | $56,303 |
| XareltoRivaroxaban | 32 | $32,308 |
| Repatha SureclickEvolocumab | 30 | $26,476 |
| FarxigaDapagliflozin Propanediol | 39 | $25,616 |
| Atorvastatin Calcium | 685 | $21,158 |
| Repatha SyringeEvolocumab | 24 | $18,084 |
| ClopidogrelClopidogrel Bisulfate | 639 | $17,020 |
| Rosuvastatin Calcium | 299 | $12,931 |
| CorlanorIvabradine Hcl | 16 | $12,459 |
| Ezetimibe | 75 | $12,386 |
| BrilintaTicagrelor | 13 | $9,269 |
| Metoprolol Succinate | 327 | $8,111 |
| Losartan Potassium | 289 | $7,175 |
| Amiodarone Hcl | 72 | $6,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $185 | $353,674333 claims |
| AstraZenecaFarxiga, Brilinta | $74 | $34,88552 claims |
| Johnson & JohnsonXarelto | $143 | $32,30832 claims |
| AmgenCorlanor | $201 | $12,45916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Houston
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Abhijeet DhobleHouston$2.7M
- John IsaacHouston$1.8M
- Amir KashaniHouston$1.3M
- Biswajit KarHouston$785K
- Michele SartoriHouston$603K
- Guilherme SilvaHouston$516K
- Sachin KumarHouston$446K
- Marwan JumeanHouston$427K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.